Adjuvant sorafenib for hepatocellular carcinoma after radiofrequency ablation versus radiofrequency ablation: analysis of its efficacy and safety
2024

Comparing Sorafenib and Radiofrequency Ablation for Liver Cancer Treatment

Sample size: 164 publication 10 minutes Evidence: moderate

Author Information

Author(s): Junxiao Wang, Rui Liu, Zhenyu Wen, Zejie Sang, Xiang Yang, Mingchao Ding, Hui Xie

Primary Institution: Fifth Medical Center of Chinese PLA General Hospital

Hypothesis

Is the combination of sorafenib with radiofrequency ablation more effective than radiofrequency ablation alone for treating early hepatocellular carcinoma?

Conclusion

Adding sorafenib to radiofrequency ablation did not improve overall survival compared to radiofrequency ablation alone, but the side effects of sorafenib were manageable.

Supporting Evidence

  • The median overall survival was 35.0 months for RFA and 41.0 months for RFA+Sor.
  • The recurrence-free survival rates at 1, 2, and 3 years were similar between the two groups.
  • Skin rashes were the only significant adverse effect noted in the RFA+Sor group.

Takeaway

Doctors wanted to see if a medicine called sorafenib helps people with liver cancer when used with a treatment called radiofrequency ablation, but it didn't make them live longer than just using radiofrequency ablation alone.

Methodology

The study included 164 patients with early hepatocellular carcinoma, comparing those who received radiofrequency ablation alone to those who received it with sorafenib, measuring overall survival and recurrence-free survival.

Potential Biases

Potential selection bias due to the retrospective nature of the study.

Limitations

The study was retrospective, and confounding factors may have influenced the outcomes.

Participant Demographics

Patients were aged 18-75, with a majority being male and having hepatitis B virus infection as the main cause of HCC.

Statistical Information

P-Value

P=0.265

Confidence Interval

95% CI: 29.99, 40.01 for OS in RFA group; 95% CI: 34.28, 47.72 for OS in RFA+Sor group

Statistical Significance

P>0.05

Digital Object Identifier (DOI)

10.3389/fonc.2024.1383312

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication